David A. Rizzieri

17.8k citations

309 papers · 8.1k indexed · 3 hit papers · h-index 44

Impact in

Hematology top 0.1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 197
- Acute Myeloid Leukemia Research 113
- Hematopoietic Stem Cell Transplantation 70
- Chronic Myeloid Leukemia Treatments 42
- Multiple Myeloma Research and Treatments 36
Genetics 73
- Chronic Lymphocytic Leukemia Research 54

Co-authors: Nelson J. Chao John P. Chute Hillard M. Lazarus Mónica L. Guzmán Craig T. Jordan Dianna S. Howard Barry Grimes Selina M. Luger
Journals: Blood (91 papers)Journal of Clinical Oncology (48 papers)Biology of Blood and Marrow Transplantation (29 papers)Bone Marrow Transplantation (11 papers)Cancer Investigation (6 papers)
Partner nations: United States France Canada

In The Last Decade

David A. Rizzieri

296 papers receiving 8.0k citations

Hit Papers

align trajectories log scale

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia 2009 · 676 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Nature
2001 Blood
2001 New England Journal of Medicine

Peers

Countries citing papers authored by David A. Rizzieri

Since Specialization

Citations

This map shows the geographic impact of David A. Rizzieri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Rizzieri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Rizzieri more than expected).

Fields of papers citing papers by David A. Rizzieri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Rizzieri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Rizzieri. The network helps show where David A. Rizzieri may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Rizzieri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Rizzieri Line = papers co-authored together David A. Rizzieri links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real‐world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies Mycoses ·Andrew Strand, Barbara D. Alexander, Eric Sarpong, Jessica Retuerto Wong, Ashley K. Engemann, David A. Rizzieri, Yuan Wu, Melissa D. Johnson	2022	2
2	A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy Transplantation and Cellular Therapy ·Lindsay Rein, David A. Rizzieri	2021	2
3	Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells Molecular Cancer Research ·Angel Y.F. Kam, Sadhna O. Piryani, Chang‐Lung Lee, David A. Rizzieri, Neil L. Spector, Stefanie Sarantopoulos, Phuong L. Doan	2021	4
4	A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia Cancer ·Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A. Rizzieri, Thomas Prébet, Christopher S. Chen, Relja Popovic, Dimple Modi, Rujuta Joshi, Johannes Wolff, Brian A. Jonas	2021	51
5	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality PLoS ONE ·Ko Ko Maung, Sendhilnathan Ramalingam, Mohammad Rauf Chaudhry, Yi Ren, Sin‐Ho Jung, Kristi Romero, Kelly Corbet, Nelson J. Chao, Taewoong Choi, Anna Mae Diehl, Louis F. Diehl, Cristina Gasparetto, Mitchell E. Horwitz, Gwynn D. Long, Richard D. Lopez, David A. Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Mustafa R. Bashir, Anthony D. Sung	2020	4
6	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations Blood ·Daniel A. Pollyea, Courtney D. DiNardo, Martha Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A. Rizzieri, Benjamin D. Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Jean Ridgeway, Hagop M. Kantarjian	2020	27
7	Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome Clinical Cancer Research ·Angel Y.F. Kam, Sadhna O. Piryani, Chad M. McCall, Hee Su Park, David A. Rizzieri, Phuong L. Doan	2019	22
8	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure Clinical Cancer Research ·Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David A. Rizzieri, Mark G. Frattini, Yair Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith	2018	74
9	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia Cancer ·Gail J. Roboz, Hagop M. Kantarjian, Karen Yee, Patricia Kropf, Casey L. O’Connell, Elizabeth A. Griffiths, Wendy Stock, Naval Daver, Elias Jabbour, Ellen K. Ritchie, Katherine Walsh, David A. Rizzieri, Scott D. Lunin, Tania Curio, Woonbok Chung, Yong Hao, James N. Lowder, Mohammad Azab, Jean‐Pierre J. Issa	2017	49
10	Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia Blood ·Aaron D. Goldberg, Martin S. Tallman, Melhem Solh, David Ungar, David A. Rizzieri, Roland B. Walter, Alexander I. Spira, Ki-Young Chung, Wendy Stock, Shui He, Joseph Boni, Ehab Atallah	2017	8
11	Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia Blood ·Anthony D. Sung, Carlos M. de Castro, Thomas W. LeBlanc, Gwynn D. Long, Donna Adams, Danielle M. Brander, Sandeep S. Davé, Louis F. Diehl, Phuong L. Doan, Therese Hennig, Yubin Kang, Matthew McKinney, Lindsay Rein, Dorothy A. Sipkins, Yiping Yang, Nelson J. Chao, David A. Rizzieri	2017	2
12	Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization Biology of Blood and Marrow Transplantation ·Sarah Anand, Samantha M. Thomas, Terry Hyslop, Janet Adcock, Kelly Corbet, Cristina Gasparetto, Richard D. Lopez, Gwynn D. Long, Ashley K. Morris, David A. Rizzieri, Keith M. Sullivan, Anthony D. Sung, Stefanie Sarantopoulos, Nelson J. Chao, Mitchell E. Horwitz	2017	27
13	Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia Nature Genetics ·Bryan Zimdahl, Takahiro Ito, Allen Blevins, Jeevisha Bajaj, Takaaki Konuma, Joi Weeks, Claire S. Koechlein, Hyog Young Kwon, Omead Arami, David A. Rizzieri, H. Elizabeth Broome, Charles Chuah, Vivian G. Oehler, Roman Šášik, Gary Hardiman, Tannishtha Reya	2014	81
14	Leukemic Stem Cells: A Review Cancer Investigation ·Jamie O'brien, David A. Rizzieri	2013	6
15	Implementation of management guidelines for chronic myeloid leukemia: perspectives in the United States. Europe PMC (PubMed Central) ·David A. Rizzieri, Joseph O. Moore	2012	10
16	Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration Bone Marrow Transplantation ·Mitchell E. Horwitz, John P. Chute, Christina Gasparetto, G D Long, Carolyn McDonald, Arthur Morris, David A. Rizzieri, Keith Sullivan, N J Chao	2011	37
17	Haploidentical Transplantation for Leukemia Current Oncology Reports ·Junya Kanda, Nelson J. Chao, David A. Rizzieri	2010	16
18	Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection Bone Marrow Transplantation ·Brian J. Byrne, Mitchell E. Horwitz, G D Long, Cristina Gasparetto, Keith M. Sullivan, John P. Chute, Nelson J. Chao, David A. Rizzieri	2007	27
19	Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer Clinical Cancer Research ·Yago Nieto, James J. Vredenburgh, Elizabeth J. Shpall, Scott I. Bearman, Peter A. McSweeney, Nelson J. Chao, David A. Rizzieri, Christina Gasparetto, Steve Matthes, Anna E. Barón, Roy B. Jones	2004	12
20	MOBILIZATION OF DENDRITIC CELLS FROM PATIENTS WITH BREAST CANCER INTO PERIPHERAL BLOOD STEM CELL LEUKAPHERESIS SAMPLES USING Flt-3-LIGAND AND G-CSF OR GM-CSF Cytokine ·Cristina Gasparetto, Maura Gasparetto, Michael A. Morse, Barbara Rooney, James J. Vredenburgh, Gwynn D. Long, David A. Rizzieri, Jennifer Loftis, Nelson J. Chao, Clay Smith	2002	20

About David A. Rizzieri

David A. Rizzieri is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Immunology, having authored 309 papers that have together received 8.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (113 papers), Hematopoietic Stem Cell Transplantation (70 papers), Chronic Lymphocytic Leukemia Research (54 papers), Acute Lymphoblastic Leukemia research (52 papers), Lymphoma Diagnosis and Treatment (48 papers), Chronic Myeloid Leukemia Treatments (42 papers), Multiple Myeloma Research and Treatments (36 papers) and CAR-T cell therapy research (33 papers). The work is most often cited by research in Hematology (4.3k citations), Genetics (1.6k citations), Oncology (2.5k citations), Immunology (1.6k citations) and Pathology and Forensic Medicine (916 citations). David A. Rizzieri has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Nelson J. Chao, John P. Chute, Hillard M. Lazarus, Mónica L. Guzmán, Craig T. Jordan, Dianna S. Howard, Barry Grimes, Selina M. Luger, Mitchell E. Horwitz and Sarah J. Neering. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation and Cancer Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact